SAN DIEGO, March 10, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced that it has been selected to presentat BIO-EuropeSpringPartnering Conference 2014,being held March 10-12 in Turin, Italy. In addition to providing an update on Arcturus' flagship program targeting transthyretin (TTR)-mediated amyloidosis utilizing its proprietary LUNARTM delivery technology and UNA Chemistry (32 patents, USPTO granted), Arcturus will present in vivo delivery of RNA to the liver and kidney. The company presentation will be on Tuesday, March 11, 5:00 PM, Room E.
"At Arcturus, we utilize exceptional and wholly-owned drug delivery technologies to empower our RNA therapeutics pipeline towards treating orphan diseases," said Zachary Zimmerman, Ph.D., Arcturus' Chief Business Officer. "The BIO-Europe Partnering Conference will be a great opportunity to introduce our business strategy to many of the world's top biotech industry executives."
About Transthyretin (TTR)-Mediated Amyloidosis
Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, which is mainly synthesized in the liver, causes errant amyloid proteins to aggregate and deposit, destroying body organs and tissue, such as the peripheral nerves and heart. TTR-mediated polyneuropathy (FAP) affects approximately 10,000 people and TTR-mediated cardiomyopathy (FAC) affects at least 40,000 people with the mean survival of ~2.5 years. With limited therapeutic options, there is a substantial unmet need for effective medicines for patients suffering from TTR-mediated diseases.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNARTM, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics. The company owns Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome. For more information, visit www.ArcturusRx.com.